Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark

Viktoria Papp; Zsolt Illes; Melinda Magyari; Nils Koch-Henriksen; Matthias Kant; Claudia Christina Pfleger; Shanu Faerch Roemer; Michael Broksgaard Jensen; Annett Evelyn Petersen; Helle Hvilsted Nielsen; Lene Rosendahl; Zsolt Mezei; Tove Christensen; Kristina Svendsen; Poul Erik Hyldgaard Jensen; Magnus Christian Lydolph; Niels Heegaard; Jette Lautrup Frederiksen; Finn Sellebjerg; Egon Stenager; Thor Petersen

doi:10.1212/WNL.0000000000006645

Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark

Viktoria Papp, Zsolt Illes, Melinda Magyari, Nils Koch-Henriksen, Matthias Kant, Claudia Christina Pfleger, Shanu Faerch Roemer, Michael Broksgaard Jensen, Annett Evelyn Petersen, Helle Hvilsted Nielsen, Lene Rosendahl, Zsolt Mezei, Tove Christensen, Kristina Svendsen, Poul Erik Hyldgaard Jensen, Magnus Christian Lydolph, Niels Heegaard, Jette Lautrup Frederiksen, Finn Sellebjerg, Egon StenagerThor Petersen

Institut for Klinisk Medicin

31 Citationer (Scopus)

52 Downloads (Pure)

Abstract

OBJECTIVES: To estimate the nationwide population-based incidence, prevalence, and geographical distribution of neuromyelitis optica (NMO) spectrum disorder (NMOSD) in Denmark based on the 2015 International Panel for NMO Diagnosis (IPND) criteria.

METHODS: We conducted a multicentre, historically prospective study. Data were sourced from the Danish National Patient Registry, the Danish Multiple Sclerosis Registry, departments of neurology, and laboratories providing aquaporin-4 antibody test. Cases were selected based on the 2006 Wingerchuk and the 2015 IPND criteria and were individually validated by an expert panel.

RESULTS: We confirmed NMO in 30 cases (2006 criteria) and NMOSD in 56 cases (2015 IPND criteria) between 2007 and 2014. Defined by the 2006 criteria, the incidence of NMO was 0.029 per 100,000 person-years (95% confidence interval [CI] 0.014-0.051), and the prevalence (aged 16 years and older) was 0.566 per 100,000 (95% CI 0.370-0.830). Based on the 2015 IPND criteria, the incidence of NMOSD was 0.070 per 100,000 person-years (95% CI 0.046-0.102), and the prevalence (aged 16 years and older) was 1.09 per 100,000 (95% CI 0.808-1.440), without regional differences.

CONCLUSIONS: Our estimates of incidence and prevalence are similar to other Caucasian population-based studies using the 2015 IPND criteria. We found no geographical clustering in Denmark.

Originalsprog	Engelsk
Tidsskrift	Neurology
Vol/bind	91
Udgave nummer	24
Sider (fra-til)	e2265-e2275
ISSN	0028-3878
DOI	https://doi.org/10.1212/WNL.0000000000006645
Status	Udgivet - 2018

Adgang til dokumentet

10.1212/WNL.0000000000006645Licens: CC BY-NC-ND

e2265.fullForlagets udgivne version, 367 KBLicens: CC BY-NC-ND

Citationsformater

Papp, V., Illes, Z., Magyari, M., Koch-Henriksen, N., Kant, M., Pfleger, C. C., Roemer, S. F., Jensen, M. B., Petersen, A. E., Nielsen, H. H., Rosendahl, L., Mezei, Z., Christensen, T., Svendsen, K., Hyldgaard Jensen, P. E., Lydolph, M. C., Heegaard, N., Frederiksen, J. L., Sellebjerg, F., ... Petersen, T. (2018). Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. Neurology, 91(24), e2265-e2275. https://doi.org/10.1212/WNL.0000000000006645

Papp, V, Illes, Z, Magyari, M, Koch-Henriksen, N, Kant, M, Pfleger, CC, Roemer, SF, Jensen, MB, Petersen, AE, Nielsen, HH, Rosendahl, L, Mezei, Z, Christensen, T, Svendsen, K, Hyldgaard Jensen, PE, Lydolph, MC, Heegaard, N, Frederiksen, JL , Sellebjerg, F, Stenager, E & Petersen, T 2018, 'Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark', Neurology, bind 91, nr. 24, s. e2265-e2275. https://doi.org/10.1212/WNL.0000000000006645

@article{7e24c1042f234f92a9aaaedf13800bdc,

title = "Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark",

abstract = "OBJECTIVES: To estimate the nationwide population-based incidence, prevalence, and geographical distribution of neuromyelitis optica (NMO) spectrum disorder (NMOSD) in Denmark based on the 2015 International Panel for NMO Diagnosis (IPND) criteria.METHODS: We conducted a multicentre, historically prospective study. Data were sourced from the Danish National Patient Registry, the Danish Multiple Sclerosis Registry, departments of neurology, and laboratories providing aquaporin-4 antibody test. Cases were selected based on the 2006 Wingerchuk and the 2015 IPND criteria and were individually validated by an expert panel.RESULTS: We confirmed NMO in 30 cases (2006 criteria) and NMOSD in 56 cases (2015 IPND criteria) between 2007 and 2014. Defined by the 2006 criteria, the incidence of NMO was 0.029 per 100,000 person-years (95% confidence interval [CI] 0.014-0.051), and the prevalence (aged 16 years and older) was 0.566 per 100,000 (95% CI 0.370-0.830). Based on the 2015 IPND criteria, the incidence of NMOSD was 0.070 per 100,000 person-years (95% CI 0.046-0.102), and the prevalence (aged 16 years and older) was 1.09 per 100,000 (95% CI 0.808-1.440), without regional differences.CONCLUSIONS: Our estimates of incidence and prevalence are similar to other Caucasian population-based studies using the 2015 IPND criteria. We found no geographical clustering in Denmark.",

author = "Viktoria Papp and Zsolt Illes and Melinda Magyari and Nils Koch-Henriksen and Matthias Kant and Pfleger, {Claudia Christina} and Roemer, {Shanu Faerch} and Jensen, {Michael Broksgaard} and Petersen, {Annett Evelyn} and Nielsen, {Helle Hvilsted} and Lene Rosendahl and Zsolt Mezei and Tove Christensen and Kristina Svendsen and {Hyldgaard Jensen}, {Poul Erik} and Lydolph, {Magnus Christian} and Niels Heegaard and Frederiksen, {Jette Lautrup} and Finn Sellebjerg and Egon Stenager and Thor Petersen",

note = "Copyright {\textcopyright} 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.",

year = "2018",

doi = "10.1212/WNL.0000000000006645",

language = "English",

volume = "91",

pages = "e2265--e2275",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams & Wilkins",

number = "24",

}

TY - JOUR

T1 - Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark

AU - Papp, Viktoria

AU - Illes, Zsolt

AU - Magyari, Melinda

AU - Koch-Henriksen, Nils

AU - Kant, Matthias

AU - Pfleger, Claudia Christina

AU - Roemer, Shanu Faerch

AU - Jensen, Michael Broksgaard

AU - Petersen, Annett Evelyn

AU - Nielsen, Helle Hvilsted

AU - Rosendahl, Lene

AU - Mezei, Zsolt

AU - Christensen, Tove

AU - Svendsen, Kristina

AU - Hyldgaard Jensen, Poul Erik

AU - Lydolph, Magnus Christian

AU - Heegaard, Niels

AU - Frederiksen, Jette Lautrup

AU - Sellebjerg, Finn

AU - Stenager, Egon

AU - Petersen, Thor

PY - 2018

Y1 - 2018

N2 - OBJECTIVES: To estimate the nationwide population-based incidence, prevalence, and geographical distribution of neuromyelitis optica (NMO) spectrum disorder (NMOSD) in Denmark based on the 2015 International Panel for NMO Diagnosis (IPND) criteria.METHODS: We conducted a multicentre, historically prospective study. Data were sourced from the Danish National Patient Registry, the Danish Multiple Sclerosis Registry, departments of neurology, and laboratories providing aquaporin-4 antibody test. Cases were selected based on the 2006 Wingerchuk and the 2015 IPND criteria and were individually validated by an expert panel.RESULTS: We confirmed NMO in 30 cases (2006 criteria) and NMOSD in 56 cases (2015 IPND criteria) between 2007 and 2014. Defined by the 2006 criteria, the incidence of NMO was 0.029 per 100,000 person-years (95% confidence interval [CI] 0.014-0.051), and the prevalence (aged 16 years and older) was 0.566 per 100,000 (95% CI 0.370-0.830). Based on the 2015 IPND criteria, the incidence of NMOSD was 0.070 per 100,000 person-years (95% CI 0.046-0.102), and the prevalence (aged 16 years and older) was 1.09 per 100,000 (95% CI 0.808-1.440), without regional differences.CONCLUSIONS: Our estimates of incidence and prevalence are similar to other Caucasian population-based studies using the 2015 IPND criteria. We found no geographical clustering in Denmark.

AB - OBJECTIVES: To estimate the nationwide population-based incidence, prevalence, and geographical distribution of neuromyelitis optica (NMO) spectrum disorder (NMOSD) in Denmark based on the 2015 International Panel for NMO Diagnosis (IPND) criteria.METHODS: We conducted a multicentre, historically prospective study. Data were sourced from the Danish National Patient Registry, the Danish Multiple Sclerosis Registry, departments of neurology, and laboratories providing aquaporin-4 antibody test. Cases were selected based on the 2006 Wingerchuk and the 2015 IPND criteria and were individually validated by an expert panel.RESULTS: We confirmed NMO in 30 cases (2006 criteria) and NMOSD in 56 cases (2015 IPND criteria) between 2007 and 2014. Defined by the 2006 criteria, the incidence of NMO was 0.029 per 100,000 person-years (95% confidence interval [CI] 0.014-0.051), and the prevalence (aged 16 years and older) was 0.566 per 100,000 (95% CI 0.370-0.830). Based on the 2015 IPND criteria, the incidence of NMOSD was 0.070 per 100,000 person-years (95% CI 0.046-0.102), and the prevalence (aged 16 years and older) was 1.09 per 100,000 (95% CI 0.808-1.440), without regional differences.CONCLUSIONS: Our estimates of incidence and prevalence are similar to other Caucasian population-based studies using the 2015 IPND criteria. We found no geographical clustering in Denmark.

U2 - 10.1212/WNL.0000000000006645

DO - 10.1212/WNL.0000000000006645

M3 - Journal article

C2 - 30413632

SN - 0028-3878

VL - 91

SP - e2265-e2275

JO - Neurology

JF - Neurology

IS - 24

ER -

Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater